A 12-month update of BOLT, a phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced or metastatic basal cell carcinoma

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: b1681f0ae0b1e0ce18290e631596898d4a7408f2
First added on: Feb 07, 2025